Abstracts tagged "psoriatic arthritis and rheumatoid arthritis (RA)"

Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 2469 • 2019 ACR/ARP Annual Meeting
Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Importance to specific T cell subpopulations has been attributed for specific diseases such as Th17 cells in psoriatic disease, Th1 cells in TB and…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 366 • 2018 ACR/ARHP Annual Meeting
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
Fatima Alduraibi¹, Monica Lawrence², Larry Borish² and Adam Carlson³, ¹Department of Medicine, University of Virginia Health System, charlottesville, VA, ²Department of Medicine, Division of Allergy and Immunology, University of Virginia Health System, Charlottesville, VA, ³Department of Medicine, Division of Rheumatology, University of Virginia Health System, Charlottesville, VA
Background/Purpose: Common variable immunodeficiency (CVID) is one of the most common symptomatic primary immunodeficiency syndrome with an incidence of ~1 in 25,000 people. CVID is…
Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Astrid Thiele⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…
Abstract Number: 1147 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany.…
Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Christian Dejaco¹, Thomas Mueller², Omid Zamani, MD³, Ulrike Kurtz, MD⁴, Stefan Egger, MD⁵, Johannes Resch Passini, MD⁶, Anna Totzauer, MD⁷, Wolfgang Eisterer⁸, Babak Yazdani-Biuki, MD, Univ.Doc.⁹, Thomas Schwingenschloegl, MD¹⁰, Peter Peichl, MD. Univ.Doc. Msc¹¹, Angelika Kraus¹², Gerhard Naerr, PhD¹³ and Verena Rickert, MD. MBA¹⁴, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Private Office Dr. Thomas Mueller, Graz, Austria, ³Rheuma Zentrum Favoriten, Vienna, Austria, ⁴Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, ⁵Ordination Gesundheitsquadrat, Vienna, Austria, ⁶Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, ⁷Private Office Dr. Anna Totzauer, Gmuend, Austria, ⁸Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, ⁹Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, ¹⁰Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, ¹¹Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, ¹²Private Office, Private Office Angelika Kraus, Melk, Austria, ¹³Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, ¹⁴Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1660 • 2018 ACR/ARHP Annual Meeting
Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
Surjeet Dheer¹, Vivekanand Tiwari², Ammarah Hussain¹, Kakageldi Hommadov¹, Ana Maheshwari¹ and Martin J. Bergman³, ¹Mercy Catholic Medical Center, Philadelphia, PA, ²St John's Hospital, Springfield, IL, ³Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Depression has been shown to be more common in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), than in the general population. The…
Abstract Number: 1983 • 2018 ACR/ARHP Annual Meeting
Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
Maria De Santis¹, Matteo Zampini², Natasa Isailovic¹, Elena Generali¹, Giacomo Maria Guidelli¹, Matteo Della Porta² and Carlo Selmi^1,3, ¹Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ²Oncology and Hematology Unit, Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: Myeloidmutations commonly associated to neoplasia in patients who do not meet the diagnostic criteria for myelodysplastic syndrome are coined as clonal hematopoiesis of indeterminate…
Abstract Number: 2060 • 2018 ACR/ARHP Annual Meeting
Comparative Histologic and Molecular Analysis of Synovial Tissue in Early Treatment-Naïve Psoriatic and Rheumatoid Arthritis
Alessandra Nerviani¹, Frances Humby¹, Gloria Lliso Ribera¹, Wang Sin Tan¹, Marie Astrid Boutet¹, Katriona Goldmann¹, Fabiola Bene¹, Rebecca Hands¹, Stephen Kelly², Michele Bombardieri³, Myles J. Lewis³, Chris Buckley⁴, Peter C. Taylor⁵, Iain B. McInnes⁶ and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Rheumatology Department, Barts Health NHS Trust, London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kindgdom, London, United Kingdom, ⁴Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ⁵University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁶Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are chronic joint conditions characterised by persistent inflammation of the synovial tissue (ST). Previous reports suggested less…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].